Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 442Stomach Neoplasms 290Rectal Neoplasms 266Colonic Neoplasms 191Pancreatic Neoplasms 175Neoplasm Metastasis 110Esophageal Neoplasms 87Neoplasms 68Carcinoma, Hepatocellular 59Adenocarcinoma Of Esophagus 47Adenocarcinoma 46Lymphoma, Large B-Cell, Diffuse 44Cholangiocarcinoma 44Carcinoma, Non-Small-Cell Lung 41Biliary Tract Neoplasms 37Gallbladder Neoplasms 30Gastrointestinal Neoplasms 29Recurrence 25Liver Neoplasms 24Ovarian Neoplasms 23Esophageal Squamous Cell Carcinoma 23Breast Neoplasms 22Peritoneal Neoplasms 17Bile Duct Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Locally Advanced Rectal Cancer 13Head and Neck Neoplasms 13Lung Neoplasms 12Lymphoma, Non-Hodgkin 11

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Efficacy and Safety × Oxaliplatin × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡